A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-20094
Latest Information Update: 06 Oct 2023
Price :
$35 *
At a glance
- Drugs HS 20094 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Jiangsu Hansen Pharmaceutical
- 18 Jul 2022 Status changed from not yet recruiting to recruiting.
- 15 Nov 2021 New trial record